Literature DB >> 9083063

Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 --> Arg and Ile523 --> val mutation.

E Wong1, C Bayly, H L Waterman, D Riendeau, J A Mancini.   

Abstract

Modeling of the active site of prostaglandin G/H synthase-2 (PGHS-2) onto PGHS-1 utilizing the known crystal structure of PGHS-1 shows that the only residues impinging directly on the active site that were not conserved in the two enzymes are His513 and Ile523 of PGHS-1 (Arg499 and Val509 of PGHS-2). These residues of human PGHS-1 were each mutated to the corresponding PGHS-2 residues (His513 --> Arg and Ile523 --> Val) and a double mutant (His513 --> Arg,Ile523 --> Val) containing both residues was also constructed. The mutant enzyme forms were expressed in COS-7 cells, and their properties were compared with those of the normal isoforms using microsomal membranes. The mutated enzyme forms all had apparent Km values within 1.4-fold that of the wild type enzyme, and the specific activity of the mutants were within 2-fold of that of PGHS-1. DuP697, NS-398, DFU, and SC-58125 are selective PGHS-2 inhibitors that act as time-dependent inhibitors of PGHS-2 and rapidly reversible competitive inhibitors of PGHS-1. The single Ile523 --> Val mutation increased the sensitivity to each of these selective inhibitors with most of the effect detected using instantaneous inhibition assays, except for DuP697, whose potency was further increased by preincubation with the enzyme. The double PGHS-1 His513 --> Arg, Ile523 --> Val mutant became more sensitive to inhibition by NS-398 and DFU than the single IV mutant, and time-dependent inhibition was observed. In contrast, the single HR mutation did not increase the sensitivity to inhibition by the selective PGHS-2 inhibitors. The potency of a selective PGHS-1 inhibitor, L-745,296, was decreased 5- and 13-fold in the HR and HR-IV mutants, respectively. All the results indicate that mutations of His513 and Ile523 residues of PGHS-1 can strongly increase sensitivity to selective PGHS-2 inhibition and restore time-dependent inhibition. They also suggest that the corresponding Arg499 and Val509 residues of PGHS-2 are essential determinants in differentiating between the interaction of nonselective NSAIDs and selective PGHS-2 inhibitors and their mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083063     DOI: 10.1074/jbc.272.14.9280

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).

Authors:  R García-Nieto; C Pérez; F Gago
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

2.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Authors:  M C Walker; R G Kurumbail; J R Kiefer; K T Moreland; C M Koboldt; P C Isakson; K Seibert; J K Gierse
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

3.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.

Authors:  A S Kalgutkar; B C Crews; S W Rowlinson; A B Marnett; K R Kozak; R P Remmel; L J Marnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  A computational protocol for the integration of the monotopic protein prostaglandin H2 synthase into a phospholipid bilayer.

Authors:  Philip W Fowler; Peter V Coveney
Journal:  Biophys J       Date:  2006-04-21       Impact factor: 4.033

5.  A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.

Authors:  C S Williams; H Sheng; J A Brockman; R Armandla; J Shao; M K Washington; A G Elkahloun; R N DuBois
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

6.  Kinetic basis for selective inhibition of cyclo-oxygenases.

Authors:  J K Gierse; C M Koboldt; M C Walker; K Seibert; P C Isakson
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

7.  Oxygenation by COX-2 (cyclo-oxygenase-2) of 3-HETE (3-hydroxyeicosatetraenoic acid), a fungal mimetic of arachidonic acid, produces a cascade of novel bioactive 3-hydroxyeicosanoids.

Authors:  Roberto Ciccoli; Shakti Sahi; Sandhya Singh; Hridayesh Prakash; Maria-Patapia Zafiriou; Ganchimeg Ishdorj; Johan L F Kock; Santosh Nigam
Journal:  Biochem J       Date:  2005-09-15       Impact factor: 3.857

8.  Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.

Authors:  C B Keerthisingam; R G Jenkins; N K Harrison; N A Hernandez-Rodriguez; H Booth; G J Laurent; S L Hart; M L Foster; R J McAnulty
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 9.  Carbocations in the synthesis of prostaglandins by the cyclooxygenase of PGH synthase? A radical departure!

Authors:  A M Dean; F M Dean
Journal:  Protein Sci       Date:  1999-05       Impact factor: 6.725

10.  Free energy perturbation approach to the critical assessment of selective cyclooxygenase-2 inhibitors.

Authors:  Hwangseo Park; Sangyoub Lee
Journal:  J Comput Aided Mol Des       Date:  2005-01       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.